Phaseline

Targets › BMP2

BMP2 (Bone morphogenetic protein 2): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 2 Phase 1, 1 Phase 4; Other; next expected readout Dec 2027.

Growth factor of the TGF-beta superfamily that plays essential roles in many developmental processes, including cardiogenesis, neurogenesis, and osteogenesis. Induces cartilage and bone formation. (UniProt, P12643)

Open in Phaseline: the race on BMP2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The University of Texas Health Science Center, HoustonDemineralized Bone Matrix/Bone Morphogenic Protein (DBM/BMP)
Bone morphogenic protein with demineralized bone matrix to promote alveolar bone formation
BMP2, BMP7Phase 4Cleft Lip and PalateJan 2028
Locate BioLDGraft 0.5mg/cc rhBMP-2
Recombinant human bone morphogenetic protein-2 (rhBMP-2) bone graft substitute
BMP2Phase 1Degenerative Disc DiseaseDec 2027

Conditions

Degenerative Disc Disease (2) Cleft Lip and Palate (1)

Modalities

small molecule (1)

Companies

The University of Texas Health Science Center, Houston (1) Locate Bio (1)

Related targets

BMP7 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.